Please login to the form below

Not currently logged in
Email:
Password:

Omthera Pharmaceuticals

This page shows the latest Omthera Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

FDA approves AZ’s fish oil drug

FDA approves AZ’s fish oil drug

It was originally developed by Omthera Pharmaceuticals – a biotech AZ purchased for $443m in 2013.

Latest news

  • Teva launches first generic of GSK's Lovaza in US Teva launches first generic of GSK's Lovaza in US

    GSK acquired US rights to Lovaza - which was originally developed by Norway's Pronova BioPharma - when it took over Reliant Pharmaceuticals in 2008 for $1.7bn. ... AZ acquired Epanova along with developer Omthera Pharmaceuticals in July 2013 in a $443m

  • Soriot says pipeline will speed recovery at AZ Soriot says pipeline will speed recovery at AZ

    Last year it bought respiratory company Pearl Therapeutics in a $1.15bn deal as well as biopharma companies AlphaCore Pharma, Spirogen, Amplimmune and Omthera Pharmaceuticals.

  • AZ said to be eyeing Forest takeover bid AZ said to be eyeing Forest takeover bid

    $500m. Earlier this year it bought respiratory company Pearl Therapeutics in a $1.15bn deal as well as US biotechs AlphaCore Pharma and Omthera Pharmaceuticals.

  • FDA to review AZ's fish oil drug Epanova FDA to review AZ's fish oil drug Epanova

    FDA to review AZ's fish oil drug Epanova. Hypertriglyceridaemia treatment acquired as part of Omthera takeover. ... Review is expected to be completed by May 2014. AZ gained rights to the drug earlier this year following its acquisition of Omthera

  • AZ adds to pipeline again with Amplimmune buy AZ adds to pipeline again with Amplimmune buy

    Therapeutics in a $1.15bn deal along with US biotechs AlphaCore Pharma and Omthera Pharmaceuticals earlier this year.

More from news
Approximately 1 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2012 Pharma deals during November 2012

    closely followed by Omthera Pharmaceuticals' Epinova, not to mention the growing concerns regarding the health benefits of premium priced prescription omega-3 fatty acids. ... Discovery research alliance. Macrocycles - small molecule drug candidates. 186.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Apex.co.uk Conferences, Events and Exhibition Stands

Apex.co.uk is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics